We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
In the latest trading session, McKesson (MCK - Free Report) closed at $719.80, marking a +1.92% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.85%. Meanwhile, the Dow experienced a rise of 1.36%, and the technology-dominated Nasdaq saw an increase of 0.72%.
Shares of the prescription drug distributor witnessed a gain of 6.5% over the previous month, beating the performance of the Medical sector with its gain of 6.01%, and the S&P 500's gain of 2.38%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $8.58, marking a 21.36% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $103.79 billion, up 10.82% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $37.21 per share and a revenue of $407.45 billion, demonstrating changes of +12.59% and +13.48%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for McKesson. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.03% lower. McKesson is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, McKesson is holding a Forward P/E ratio of 18.98. This signifies a premium in comparison to the average Forward P/E of 15 for its industry.
Also, we should mention that MCK has a PEG ratio of 1.4. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.78.
The Medical - Dental Supplies industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 163, placing it within the bottom 35% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Outperforms Broader Market: What You Need to Know
In the latest trading session, McKesson (MCK - Free Report) closed at $719.80, marking a +1.92% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.85%. Meanwhile, the Dow experienced a rise of 1.36%, and the technology-dominated Nasdaq saw an increase of 0.72%.
Shares of the prescription drug distributor witnessed a gain of 6.5% over the previous month, beating the performance of the Medical sector with its gain of 6.01%, and the S&P 500's gain of 2.38%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $8.58, marking a 21.36% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $103.79 billion, up 10.82% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $37.21 per share and a revenue of $407.45 billion, demonstrating changes of +12.59% and +13.48%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for McKesson. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.03% lower. McKesson is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, McKesson is holding a Forward P/E ratio of 18.98. This signifies a premium in comparison to the average Forward P/E of 15 for its industry.
Also, we should mention that MCK has a PEG ratio of 1.4. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.78.
The Medical - Dental Supplies industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 163, placing it within the bottom 35% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.